/

Empresas

Ge

No verificado

Genentech

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

82 Comunicados de prensa

Ver todos los comunicados de prensa

30/04/2026

Eventos

Ferias y Congresos

Industria

Ciencia

Biotecnología

Farmacéutica

Óptica

Sanidad

Salud

Medicina - Varios

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

Fuente

Editor

1.00

0

24/04/2026

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

Fuente

Editor

1.00

0

21/04/2026

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Fuente

Editor

1.00

0

21/04/2026

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

Fuente

Editor

1.00

0

21/04/2026

Eventos

Ferias y Congresos

Industria

Salud

Higiene alimentaria

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Fuente

Editor

1.00

0

21/04/2026

Eventos

Ferias y Congresos

Industria

Salud

Higiene alimentaria

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Fuente

Editor

1.00

0

09/03/2026

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Farmacéutica

Ir de compras

Salud

Oncología

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Fuente

Editor

1.00

0

06/03/2026

Industria

Biotecnología

Farmacéutica

Salud

Medicina - Varios

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Fuente

Editor

1.00

0

05/03/2026

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

Fuente

Editor

1.00

0

02/03/2026

Industria

Salud

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0